Targeting lipid mediators in cancer biology

[1]  B. Schmidt,et al.  Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma , 2018, Neuropharmacology.

[2]  Charles N Serhan,et al.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. , 2018, Journal of Clinical Investigation.

[3]  R. DuBois,et al.  Role of prostanoids in gastrointestinal cancer. , 2018, The Journal of clinical investigation.

[4]  Y. Surh,et al.  RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. , 2018, Biochemical and biophysical research communications.

[5]  Sui Huang,et al.  Resolvins suppress tumor growth and enhance cancer therapy , 2018, The Journal of experimental medicine.

[6]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[7]  Wenjun Wang,et al.  Potential plasma lipid biomarkers in early-stage breast cancer , 2017, Biotechnology Letters.

[8]  R. Melillo,et al.  Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways , 2017, Oncoimmunology.

[9]  A. Wright,et al.  Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products , 2017, Anti-cancer drugs.

[10]  I. Roitt,et al.  Lipoxin A4 selectively programs the profile of M2 tumor‐associated macrophages which favour control of tumor progression , 2017, International journal of cancer.

[11]  C. Serhan,et al.  Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages , 2016, Proceedings of the National Academy of Sciences.

[12]  Wen-hui Li,et al.  Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress. , 2016, International journal of molecular medicine.

[13]  N. Sharma-Walia,et al.  Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis , 2016, Journal of Virology.

[14]  Y. Kanai,et al.  Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.

[15]  Youping Deng,et al.  Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions , 2016, Oncotarget.

[16]  B. Zhu,et al.  Lipidome in colorectal cancer , 2016, Oncotarget.

[17]  R. DuBois,et al.  Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. , 2015, Gastroenterology.

[18]  Bhupinder Bhullar,et al.  Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human , 2015, Oncotarget.

[19]  Katherine M Flegal,et al.  Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. , 2015, NCHS data brief.

[20]  Shanshan Liu,et al.  Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production , 2015, Scientific Reports.

[21]  Z. Wang,et al.  Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. , 2015, Cancer Letters.

[22]  R. Glynn,et al.  Prospective study of body size throughout the life‐course and the incidence of endometrial cancer among premenopausal and postmenopausal women , 2015, International journal of cancer.

[23]  M. Kömhoff,et al.  Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro , 2015, Mediators of inflammation.

[24]  K. Larsson,et al.  COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset , 2015, Proceedings of the National Academy of Sciences.

[25]  M. Fiala,et al.  Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production , 2015, Front. Physiol..

[26]  N. Boyd,et al.  Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. , 2015, Journal of the National Cancer Institute.

[27]  X. Terra,et al.  Prostacyclin‐synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy , 2015, The Journal of pathology.

[28]  Philip Levy Ho,et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.

[29]  Yinghua Xu,et al.  Body mass index and risk of renal cell cancer: A dose‐response meta‐analysis of published cohort studies , 2014, International journal of cancer.

[30]  Nada B. Memon,et al.  Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion. , 2014, International journal of cardiology.

[31]  Honghe Zhang,et al.  Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer , 2014, International journal of cancer.

[32]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[33]  T. Tsujiuchi,et al.  Diverse effects of LPA receptors on cell motile activities of cancer cells , 2014, Journal of receptor and signal transduction research.

[34]  R. Lamuela-Raventós,et al.  Dietary intake of vitamin K is inversely associated with mortality risk. , 2014, Journal of NutriLife.

[35]  P. Couvreur,et al.  Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. , 2014, Chemical communications.

[36]  I. Thompson,et al.  Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.

[37]  K. Goralski,et al.  Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells , 2014, Anti-cancer drugs.

[38]  P. Faust,et al.  Cholesterol biosynthesis and ER stress in peroxisome deficiency. , 2014, Biochimie.

[39]  Hyundoo Hwang,et al.  RhoA and Rac1 play independent roles in lysophosphatidic acid-induced ovarian cancer chemotaxis. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[40]  P. Couvreur,et al.  Therapeutic Modalities of Squalenoyl Nanocomposites in Colon Cancer: An Ongoing Search for Improved Efficacy , 2014, ACS nano.

[41]  D. Giugliano,et al.  Metabolic syndrome and endometrial cancer: a meta-analysis , 2014, Endocrine.

[42]  E. Larsson,et al.  Antioxidants Accelerate Lung Cancer Progression in Mice , 2014, Science Translational Medicine.

[43]  J. Liao,et al.  C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia , 2013, PloS one.

[44]  M. Park,et al.  Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. , 2013, The international journal of biochemistry & cell biology.

[45]  A. Ananthaneni,et al.  Evaluation and correlation of serum lipid profile in oral and gastrointestinal cancer patients. , 2013, Journal of international oral health : JIOH.

[46]  M. Underwood,et al.  Thromboxane A2 receptor α promotes tumor growth through an autoregulatory feedback pathway. , 2013, Journal of molecular cell biology.

[47]  Jeff S. Jasper,et al.  27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology , 2013, Science.

[48]  M. Peppelenbosch,et al.  DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells , 2013, International journal of molecular medicine.

[49]  L. T. Tan.  Pharmaceutical agents from filamentous marine cyanobacteria. , 2013, Drug discovery today.

[50]  Gabor Tigyi,et al.  Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression , 2013, Cancer Immunology Research.

[51]  C. Serhan,et al.  Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.

[52]  T. G. Grunewald,et al.  Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: A focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays , 2013, Biology of the cell.

[53]  N. Geng,et al.  Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis , 2013, Current medical research and opinion.

[54]  Dale P Sandler,et al.  Association between Urinary Prostaglandin E2 Metabolite and Breast Cancer Risk: A Prospective, Case–Cohort Study of Postmenopausal Women , 2013, Cancer Prevention Research.

[55]  L. Degraffenried,et al.  A Low Dietary Ratio of Omega-6 to Omega-3 Fatty Acids May Delay Progression of Prostate Cancer , 2013, Nutrition and cancer.

[56]  Liangtao Zhang,et al.  Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[57]  S. Pyne,et al.  The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. , 2013, Cellular signalling.

[58]  M. Barbacid,et al.  Genetically engineered mouse models of pancreatic adenocarcinoma , 2013, Molecular oncology.

[59]  C. Hudis,et al.  Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer , 2013, Cancer Prevention Research.

[60]  Xiaoman Liu,et al.  IFN-γ-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. , 2013, Cancer research.

[61]  Mikio Suzuki,et al.  Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells , 2013, International journal of oncology.

[62]  H. Tai,et al.  Activation of Thromboxane A2 Receptor (TP) Increases the Expression of Monocyte Chemoattractant Protein -1 (MCP-1)/Chemokine (C-C motif) Ligand 2 (CCL2) and Recruits Macrophages to Promote Invasion of Lung Cancer Cells , 2013, PloS one.

[63]  Yongzhi Yang,et al.  Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies , 2013, PloS one.

[64]  Dezhi Yang,et al.  Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2 , 2013, Oncology letters.

[65]  A. Colquhoun,et al.  E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro , 2012, Lipids in Health and Disease.

[66]  F. Tomasello,et al.  PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation , 2012, Epigenetics.

[67]  Belgin Dogan,et al.  Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota , 2012, Science.

[68]  Y. Peterson,et al.  Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy , 2012, Nature chemical biology.

[69]  Yasuhiro Yamamoto,et al.  Cytotoxicity of 15-Deoxy-Δ12,14-prostaglandin J2 through PPARγ-independent Pathway and the Involvement of the JNK and Akt Pathway in Renal Cell Carcinoma , 2012, International journal of medical sciences.

[70]  Jianjun Luo,et al.  Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. , 2012, European journal of cancer.

[71]  R. Weinberg,et al.  Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. , 2012, Cancer discovery.

[72]  M. Caleo,et al.  New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase , 2012, Neuropharmacology.

[73]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[74]  P. Couvreur,et al.  Squalenoylation: a generic platform for nanoparticular drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[75]  Venkatesh Kota,et al.  Identification of C6‐ceramide‐interacting proteins in D6P2T Schwannoma cells , 2012, Proteomics.

[76]  N. Shinohara,et al.  Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner , 2012, Cancer science.

[77]  C. Serhan,et al.  Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. , 2012, The American journal of pathology.

[78]  Y. Daaka,et al.  PGE2 Promotes Renal Carcinoma Cell Invasion through Activated RalA , 2012, Oncogene.

[79]  Q. Zeng,et al.  Association of Dyslipidemia with Renal Cell Carcinoma: A 1∶2 Matched Case-Control Study , 2012, PloS one.

[80]  S. Narumiya,et al.  Thromboxane A2 receptor signaling facilitates tumor colonization through P‐selectin‐mediated interaction of tumor cells with platelets and endothelial cells , 2012, Cancer science.

[81]  Y. Hannun,et al.  Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction , 2012, Molecular Cancer Therapeutics.

[82]  Tara Karnezis,et al.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.

[83]  Eugene Y. Kim,et al.  Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. , 2012, Cancer research.

[84]  Y. Urade,et al.  Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma , 2011, Proceedings of the National Academy of Sciences.

[85]  Sui Huang,et al.  Regulation of inflammation in cancer by eicosanoids. , 2011, Prostaglandins & other lipid mediators.

[86]  M. Maggiolini,et al.  Glycerophospholipid synthesis as a novel drug target against cancer. , 2011, Current molecular pharmacology.

[87]  K. Honn,et al.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis , 2011, Cancer and Metastasis Reviews.

[88]  K. Honn,et al.  Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment , 2011, Cancer and Metastasis Reviews.

[89]  J. Crowley,et al.  The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2011 .

[90]  M. Cabot,et al.  Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer , 2011, Cancer biology & therapy.

[91]  Y. Daaka,et al.  Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction Pathway* , 2011, The Journal of Biological Chemistry.

[92]  S. Pyne,et al.  FTY720 Analogues as Sphingosine Kinase 1 Inhibitors , 2011, The Journal of Biological Chemistry.

[93]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[94]  C. Serhan,et al.  Novel anti-inflammatory--pro-resolving mediators and their receptors. , 2011, Current topics in medicinal chemistry.

[95]  M. Underwood,et al.  4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor , 2011, Oncogene.

[96]  E. Mallon,et al.  High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. , 2010, The American journal of pathology.

[97]  Y. Miller,et al.  Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. , 2010, Lung cancer.

[98]  D. Ye,et al.  Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis , 2010, Molecular Cancer Therapeutics.

[99]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[100]  A. Nohturfft,et al.  Coordination of lipid metabolism in membrane biogenesis. , 2009, Annual review of cell and developmental biology.

[101]  J. Klenk,et al.  Serum triglyceride concentrations and cancer risk in a large cohort study in Austria , 2009, British Journal of Cancer.

[102]  G. Nicolini,et al.  Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies , 2009, Neurobiology of Disease.

[103]  C. Serhan,et al.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.

[104]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[105]  T. Karn,et al.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer , 2008, Breast Cancer Research and Treatment.

[106]  J. Kwak,et al.  15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation , 2007, Apoptosis.

[107]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[108]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[109]  Tianxin Yang,et al.  Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. , 2006, American journal of physiology. Renal physiology.

[110]  P. Couvreur,et al.  Squalenoyl nanomedicines as potential therapeutics. , 2006, Nano letters.

[111]  M. Monden,et al.  Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology , 2006, British Journal of Cancer.

[112]  S. Solomon,et al.  Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.

[113]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[114]  Korey R. Johnson,et al.  ©2005 FASEB The FASEB Journal express article 10.1096/fj.05-4331fje. Published online November 30, 2005. Sphingosine kinase 1 is up-regulated in colon carcinogenesis , 2022 .

[115]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[116]  S. Dudek,et al.  Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[117]  C. Serhan.  Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[118]  R. DuBois,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[119]  A. Mantovani,et al.  Cancer: Inflammation by remote control , 2005, Nature.

[120]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[121]  Jennifer Couzin,et al.  Withdrawal of Vioxx Casts a Shadow Over COX-2 Inhibitors , 2004, Science.

[122]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[123]  K. Maeyama,et al.  The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. , 2004, Biochemical pharmacology.

[124]  J. Abrams,et al.  Sphingomyelin in the suppression of colon tumors: prevention versus intervention. , 2003, Archives of biochemistry and biophysics.

[125]  G. Anderson,et al.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.

[126]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[127]  C. Serhan,et al.  Resolvins , 2002, The Journal of Experimental Medicine.

[128]  Xìao-chun Xu.  COX-2 inhibitors in cancer treatment and prevention, a recent development. , 2002, Anti-cancer drugs.

[129]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[130]  H. Rüdiger,et al.  Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. , 2001, Cancer research.

[131]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[132]  E. Gelmann,et al.  Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. , 2000, Cancer research.

[133]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[134]  V. Steele,et al.  Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. , 2000, Cancer research.

[135]  B. Chung,et al.  Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. , 1999, Clinical biochemistry.

[136]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[137]  M. Peters-Golden,et al.  Arachidonic Acid Is Preferentially Metabolized by Cyclooxygenase-2 to Prostacyclin and Prostaglandin E2 * , 1999, The Journal of Biological Chemistry.

[138]  K. Savin,et al.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[139]  T. MacDonald,et al.  Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study , 1997, BMJ.

[140]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[141]  L. Crofford,et al.  COX-1 and COX-2 tissue expression: implications and predictions. , 1997, The Journal of rheumatology. Supplement.

[142]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[143]  R. Kolesnick,et al.  Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase , 1997, Cell.

[144]  J. Pfeilschifter,et al.  Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[145]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[146]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[147]  G. L. Le Breton,et al.  Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. , 1993, The Journal of biological chemistry.

[148]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[149]  J. Lindgren,et al.  Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. , 1991, Blood.

[150]  C. Hamilton,et al.  Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function , 1991, Journal of clinical pharmacology.

[151]  S. Nakanishi,et al.  Cloning and expression of cDNA for a human thromboxane A2 receptor , 1991, Nature.

[152]  B. Samuelsson.  From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences , 1983 .

[153]  W. Waddell,et al.  Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.

[154]  J. Oates,et al.  Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. , 1982, Journal of immunology.

[155]  Robert A. Lewis,et al.  Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds , 1981, Nature.

[156]  J. Robertson,et al.  Synthesis of Prostaglandins and Thromboxane B2 by Cerebral Arteries , 1979, Stroke.

[157]  A. Tashjian.  Role of prostaglandins in the production of hypercalcemia by tumors. , 1978, Cancer research.

[158]  T. Żebro,et al.  PROSTAGLANDINS AND BREAST CANCER , 1977, The Lancet.

[159]  T. Żebro,et al.  Prostaglandins from tumours of human large bowel. , 1977, British Journal of Cancer.

[160]  A. Tashjian,et al.  Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells , 1975, Nature.

[161]  A. Tashjian,et al.  Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. , 1973, Prostaglandins.

[162]  A. Tashjian,et al.  Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. , 1972, Biochemical and biophysical research communications.

[163]  S. Singer,et al.  The Fluid Mosaic Model of the Structure of Cell Membranes , 1972, Science.

[164]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[165]  D. Klein,et al.  Prostaglandins: stimulation of bone resorption in tissue culture. , 1970, Endocrinology.

[166]  E. Corey,et al.  A new total synthesis of prostaglandins of the E1 and F1 series including 11-epiprostaglandins. , 1968, Journal of the American Chemical Society.

[167]  E. Corey,et al.  Total synthesis of prostaglandins. Synthesis of the pure dl-E1, -F(sub 1.alpha.), -F(sub 1.beta.), -A1, and -B1 hormones , 1968 .

[168]  E. V. Van Scott,et al.  The modulating influence of stromal environment on epithelial cells studied in human autotransplants. , 1961, The Journal of investigative dermatology.

[169]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[170]  U. S. Euler.  On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). , 1936 .

[171]  Cuthbert Dukes,et al.  Origin of Cancer , 1938 .

[172]  Haoyu Kuang,et al.  Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-κB activity. , 2016, Oncology reports.

[173]  Sung-Dae Cho,et al.  Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. , 2013, Cancer letters.

[174]  S. Saddoughi,et al.  Diverse functions of ceramide in cancer cell death and proliferation. , 2013, Advances in cancer research.

[175]  M. Kester,et al.  Development and use of ceramide nanoliposomes in cancer. , 2012, Methods in enzymology.

[176]  Kathryn A. Newman,et al.  A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. , 2011, Nutrition research.

[177]  A. Hezel,et al.  Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma , 2011 .

[178]  J. Liou,et al.  Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta --> 14-3-3epsilon pathway. , 2009, Methods in molecular biology.

[179]  S. Pettersson,et al.  Cancer Inflammation , 2009, Mucosal Immunology.

[180]  G. van Meer,et al.  Cellular lipidomics , 2005, The EMBO journal.

[181]  J. Couzin.  Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. , 2004, Science.

[182]  B. Evers,et al.  Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. , 2002, International journal of gastrointestinal cancer.

[183]  B. Evers,et al.  Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells , 2002 .

[184]  H. Seyberth,et al.  Localization of the prostacyclin receptor in human kidney. , 1998, Kidney international.

[185]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[186]  T. B. Osborne,et al.  Nutrition classics from The Journal of Biological Chemistry 20:379-389, 1915. Further observations of the influence of natural fats upon growth. , 1973, Nutrition reviews.